Sep 24 |
NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's
|
Sep 24 |
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule
|
Aug 7 |
NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market Price
|
Aug 1 |
NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical Trial
|
Jun 24 |
NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results
|
Jun 21 |
NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal
|
May 14 |
NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning
|
May 2 |
NeuroSense Announces First Quarter 2024 Business Update
|
Apr 22 |
NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease
|
Apr 18 |
NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting
|